Daiichi Sankyo poised to enter Japan's generics sector
This article was originally published in Scrip
Daiichi Sankyo is to set up a new operation in Japan for the manufacture and marketing of its own mature products as well as generics sourced from Ranbaxy Laboratories, in a move designed to build on its 2008 acquisition of the Indian firm.
You may also be interested in...
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.
Cancer deals involving Junshi/Wigen, Allist/Octimet, Yufan/Abound, Takeda/Presage, Daiichi Sankyo/AnHeart, LegoChem/Harbour Biomed, plus a stem cell partnership and a lysosomal storage disorder agreement.
Japan coordinates initiative to improve regional early-stage development of novel cancer therapies, which will work both with the industry and independently to improve access.